Paul L. Prather - Concepedia

Author

Paul L. Prather

University of Arkansas for Medical Sciences ORCID

Also Known As

P L Prather, P PRATHER, P. L. Prather, P. Prather, P.L. Prather, PAUL L. PRATHER, Paul L Prather, Paul L. Prather, Paul Prather, Paxton Prather

123

Publications

4.7K

Citations

H-Index

Concepts

All Affiliations

University of Arkansas for Medical Sciences Arkansas Department of Health University of Minnesota Cayman Chemical (United States)Texas College

About

Paul L. Prather is an author at University of Arkansas for Medical Sciences specializing in medicine, pharmacology, and neuropharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	30	1.6K
2	Biochemistry	11	12	610
3	Health Sciences	5	5	347
4	Social Sciences	5	5	265
5	Natural Sciences	3	3	159

Paul L. Prather

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and Activity Lisa K. Brents, Emily E. Reichard, Sarah M. Zimmerman, PLoS ONE	2011	210
The CB2 cannabinoid agonist AM‐1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset Jennifer L. Shoemaker, Kathryn A. Seely, Ronald L. Reed, Journal of Neurochemistry	2007	207
Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor Ligands Krishna C. Chimalakonda, Kathryn A. Seely, Stacie M. Bratton, Drug Metabolism and Disposition	2012	183
Activation of Cannabinoid CB2 Receptor–Mediated AMPK/CREB Pathway Reduces Cerebral Ischemic Injury In Young Choi, Chung Ju, Angela M. A. Anthony Jalin, American Journal Of Pathology Cannabis UseMolecular NeuroscienceIschemic StrokeNeurophysiologyMedicine	2013	152
Characterization of Human Hepatic and Extrahepatic UDP-Glucuronosyltransferase Enzymes Involved in the Metabolism of Classic Cannabinoids Anna Mazur, Cheryl F. Lichti, Paul L. Prather, Drug Metabolism and Disposition	2009	149
Quantitative Measurement of JWH-018 and JWH-073 Metabolites Excreted in Human Urine Cindy L. Moran, Vi-Huyen Le, Krishna C. Chimalakonda, Analytical Chemistry	2011	148
Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity Lisa K. Brents, Anna Gallus‐Zawada, Anna Radomińska‐Pandya, Biochemical Pharmacology Cannabis UsePartial Agonist ActivityBiochemistryFunctional SelectivityMedicine	2012	142
Agonist-Directed Trafficking of Response by Endocannabinoids Acting at CB2 Receptors Jennifer L. Shoemaker, Michael B. Ruckle, Philip R. Mayeux, Journal of Pharmacology and Experimental Therapeutics	2005	130
Forensic investigation of K2, Spice, and “bath salt” commercial preparations: A three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds Kathryn A. Seely, Amy Patton, Cindy L. Moran, Forensic Science International Cannabis UseThree-year StudyMedicineDrug PurityForensic Toxicology	2013	107
Expression of the μ‐Opioid Receptor in CHO Cells: Ability of μ‐Opioid Ligands to Promote α‐Azidoanilido[<sup>32</sup>P]GTP Labeling of Multiple G Protein α Subunits Sumita Chakrabarti, Paul L. Prather, Lei Yu, Journal of Neurochemistry	1995	107

Page 1